HomeCompareRDSMY vs PFE

RDSMY vs PFE: Dividend Comparison 2026

RDSMY yields 29.34% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RDSMY wins by $259.66M in total portfolio value
10 years
RDSMY
RDSMY
● Live price
29.34%
Share price
$33.85
Annual div
$9.93
5Y div CAGR
42%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$259.71M
Annual income
$216,211,959.52
Full RDSMY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RDSMY vs PFE

📍 RDSMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRDSMYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RDSMY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RDSMY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RDSMY
Annual income on $10K today (after 15% tax)
$2,493.58/yr
After 10yr DRIP, annual income (after tax)
$183,780,165.59/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RDSMY beats the other by $183,757,845.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RDSMY + PFE for your $10,000?

RDSMY: 50%PFE: 50%
100% PFE50/50100% RDSMY
Portfolio after 10yr
$129.88M
Annual income
$108,119,109.12/yr
Blended yield
83.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RDSMY
Analyst Ratings
2
Buy
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RDSMY buys
0
PFE buys
0
No recent congressional trades found for RDSMY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRDSMYPFE
Forward yield29.34%6.13%
Annual dividend / share$9.93$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR42%13.2%
Portfolio after 10y$259.71M$49.6K
Annual income after 10y$216,211,959.52$26,258.71
Total dividends collected$256.08M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: RDSMY vs PFE ($10,000, DRIP)

YearRDSMY PortfolioRDSMY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$14,866$4,165.74$9,153$693.39+$5.7KRDSMY
2$24,125$8,218.32$8,593$849.25+$15.5KRDSMY
3$43,513$17,699.56$8,336$1,066.78+$35.2KRDSMY
4$88,926$42,366.66$8,437$1,384.80+$80.5KRDSMY
5$210,055$114,904.40$9,013$1,875.40+$201.0KRDSMY
6$584,961$360,202.96$10,306$2,680.72+$574.7KRDSMY
7$1,957,119$1,331,210.45$12,820$4,101.38+$1.94MRDSMY
8$8,004,850$5,910,732.36$17,673$6,826.70+$7.99MRDSMY
9$40,648,692$32,083,502.25$27,543$12,591.86+$40.62MRDSMY
10$259,706,060$216,211,959.52$49,560$26,258.71+$259.66MRDSMY

RDSMY vs PFE: Complete Analysis 2026

RDSMYStock

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, premixes, carotenoids, enzymes, microbes, and eubiotics; human nutrition and health products comprising vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics, and prebiotics, as well as active pharmaceutical ingredients; premix, market-ready solutions, and personalized nutrition; human milk oligosaccharides; and skin and sun care, hair care, and aroma ingredients; omega-3 fatty acids; and specialty food enzymes, cultures, bio-preservation, texturizing hydrocolloids, sugar reduction, and savory taste solutions. The Materials segment provides specialty plastics used in components for the electrical and electronics, automotive, flexible food-packaging, and consumer goods industries; and Dyneema, a fiber solution for use in personal protection, workwear, sports apparel, outdoor equipment, ropes and slings, synthetic chains, and nets for the aquaculture, and renewable energy sectors. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, continence care, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, peripheral vascular, plastic and reconstructive surgery, and wound management. It also commercializes yeast technology yeast for ethanol production. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

Full RDSMY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RDSMY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RDSMY vs SCHDRDSMY vs JEPIRDSMY vs ORDSMY vs KORDSMY vs MAINRDSMY vs JNJRDSMY vs MRKRDSMY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.